Neurofibromatosis Pipeline Insight
DelveInsight’s, “Neurofirbromatosis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Neurofirbromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Neurofibromatosis (NF) is a genetic disorder that causes tumors to develop in the brain, spinal cord, and nerves. The condition occurs as a result of a gene abnormality. There are two types of NF, both of which cause tumor growth in various areas of the body. Neurofibromatosis type 1 (NF1) is more common than neurofibromatosis type 2 (NF2). NF1 causes tumors to form in various tissues and organs of the body. This causes skin problems and bone deformities. NF2, on the other hand, causes tumors to develop on the brain and spinal nerves. Although most tumors caused by NF are not cancerous, they can still be dangerous and impair your quality of life.
"Neurofirbromatosis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofirbromatosis pipeline landscape is provided which includes the disease overview and Neurofirbromatosis treatment guidelines. The assessment part of the report embraces, in depth Neurofirbromatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofirbromatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Neurofirbromatosis R&D. The therapies under development are focused on novel approaches to treat/improve Neurofirbromatosis.
Neurofirbromatosis Emerging Drugs Chapters
This segment of the Neurofirbromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neurofirbromatosis Emerging Drugs
NFX-179: NFlection Therapeutics
NFlection is developing a topical gel containing NFX-179, a proprietary “soft” (metabolically labile) MEK inhibitor for the reduction of tumor burden of persistently developing cutaneous neurofibromas (cNF) in neurofibromatosis type 1 (NF1). NFlection has developed an esthetically pleasing and well-tolerated topical formulation of the MEK inhibitor NFX-179 to treat cNFs. NFX-179 has been tested on human cNF explants and has demonstrated dose-dependent suppression of p-ERK, a biomarker of Ras/Raf/MEK/ERK pathway activation. The NFX-179 gel formulation can penetrate into the dermis of the skin to locally deliver the MEK inhibitor to the cNF and inhibit the overactive RAS pathway in the tumor. NFX-179 rapidly degrades upon reaching systemic circulation to minimize the side effects caused by systemic exposure to MEK inhibitors.
Mirdametinib: SpringWorks Therapeutics
Mirdametinib is an oral, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1‑associated plexiform neurofibromas, or NF1‑PN, and as a combination therapy for the treatment biomarker defined metastatic cancers with mutations in the MAPK pathway, such as in RAS and RAF. Mirdametinib is designed to inhibit MEK1 and MEK2. MEK proteins occupy a pivotal position in the MAPK pathway, which is a key signaling network that regulates cell growth and survival, and that plays a central role in multiple oncology and rare disease indications. The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients ≥ 2 years of age with NF1-PN that are progressing or causing significant morbidity.
Further product details are provided in the report……..
Neurofirbromatosis: Therapeutic Assessment
This segment of the report provides insights about the different Neurofirbromatosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Neurofirbromatosis
There are approx. 10+ key companies which are developing the therapies for Neurofirbromatosis. The companies which have their Neurofirbromatosis drug candidates in the mid to advanced stage, i.e. phase II include, NFlection Therapeutics and others.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Neurofirbromatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Neurofirbromatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofirbromatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofirbromatosis drugs.
Neurofirbromatosis Report Insights
- Neurofirbromatosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Neurofirbromatosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neurofirbromatosis drugs?
- How many Neurofirbromatosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurofirbromatosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neurofirbromatosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neurofirbromatosis and their status?
- What are the key designations that have been granted to the emerging drugs?